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Aim. To investigate the ability of «core» 2'-5'- and 3'-5'-oligo- adenylates (OA) to interact with -interferon – a
key protein of the 2'- 5'-OAS/RNAase L system responsible for antiviral cell defense. Methods. MALDI-TOF
mass spectrometry was used in the studies on protein-li- gand interactions. Results. It was shown that 2'-5'-À
3
and its epoxy-modified analog 2'-5'-À
3
-epo can bind to -interferon in vitro. 3'-5'-triadenylate is also capable of
binding to this protein. One to five ligand molecules can bind simultaneously to the molecule of -interferon. At
the same time, all studied oligonucleotides do not bind to insulin. Con- clusions. It was established that «core»
2'-5'- and 3'-5'-triadenylates are capable of multiple interaction with -interferon to form stable complexes.
However, they do not bind to insulin which is not involved in the 2'-5'-OAS/RNAase L system.
Keywords: oligoadenylates, insulin, -interferon, MALDI-TOF mass spectrometry.
Introduction. In recent years oligoriboadenylates and
their analogues have been studied even more actively
than ever before as they are considered to be promising
compounds for the elaboration of novel antiviral, anti-
inflammatory and antitumor agents [1–6]. They play a
key role in the mechanism of antiviral defense of the
cell and are also involved in the processes of cell
growth and differentiation, apoptosis, pathogenesis of
diabetes, atherosclerosis, etc. Numerous works on the
investigation of biological activity of 2’-5’-oligo-
adenylates (2-5À) demonstrate that their mechanism of
antiviral activity is related to the capability of affecting
the proteins of 2’-5’-oligoadenylate synthetase/endo-
ribonuclease L system (2’-5’-OAS/RNAse L) which,
in turn, leads to the elimination of viral RNA [1, 7–11].
At present there are a number of investigated pro-
teins required for the functioning of the cellular system
of antiviral protection. First, this is RNAse L that
cleaves single-stranded viral RNA [1, 7, 12], protein
kinase R controlling the synthesis of viral proteins [13],
and protein Mx responsible for special activity against
influenza virus [14]. However, the main role in the
antiviral protection is attributed to interferons, which
induce the expression of genes involved in the antiviral
activity of the cell, and as well are capable of inde-
pendent activation by the products of the cleavage of
hepatitis C virus RNA by RNAse L, as proven by recent
studies of Silverman [15]. While binding to protein
RIG-I, these oligoribonucleotides stimulate its ATPase
activity and, consequently, that of b-interferon gene,
the product of which, in turn, induces 2’-5’-oligo-
adenylate synthetase and the synthesis of 2-5A tri-
phosphates.
Therefore, the hydrolysis products of viral RNA are
capable of activating interferon synthesis. Still there is
a question of possible ability of “core” (non-phospho-
rylated) 2-5A, as well as 3’-5’-oligoadenylates, to inter-
act directly with interferon and thus affect its functions.
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One of the modern methods to study this problem is
MALDI-TOF mass spectrometry (Matrix-Assisted La-
ser Desorption/Ionization Time-Of-Flight mass spec-
trometry). This method is successfully used to investi-
gate biomolecules: aminoacids [16], peptides and
proteins [17, 18], oligonucleotides and nucleic acids
[19–22]. In particular, this approach allows studying
their modification, the ways of fragmentation, the
structure of covalent and non-covalent complexes, etc.
MALDI-TOF method is applied even wider for fast and
reliable determination of both nucleotide and amino-
acid sequences, as well as for the identification of
proteins in RNA-protein complexes [21–23]. For in-
stance, mass spectrometry has been successfully em-
ployed to sequence oligoribonucleotides containing up
to 22 nucleotides, and a number of proteins and pe-
ptide-RNA complexes in ribonucleoproteins [21, 24].
The analysis of mass spectrometry data ensures
high accuracy of determining the molecular mass of the
substance, the purity of the investigated sample and the
identification of possible impurities. This method
makes it possible to detect proteins in complex
mixtures, to study the modification of biopolymers
(glycosylation or phosphorylation of proteins, DNA
methylation, etc.) [18, 22, 23]. The key feature of
mass-spectrometric methods of analysis, including
MALDI-TOF, the most significant for the current
work, is broad possibilities of the study on
non-covalent interaction in biopolymer complexes, e.g.
protein-protein, protein-nucleic interactions, etc. [18,
22, 24–28].
An important stage in the determination of probable
mechanisms of antiviral activity of oligoadenylates is
investigation of the specificities of their interaction
with target proteins participating in the antiviral
protection of the cell, such as interferon. The current
work is aimed at the in vitro study on binding of
á-interferon and insulin (a control protein that is not
involved in the 2’-5’-OAS/RNAse L system) with a
number of oligoadenylates of different structure using
MALDI-TOF method.
Materials and Methods. 2’-5’-Triadenylate
2’-5’-À3 and its epoxy analogue 2’-5’-À3-epo were
synthesized by [the] phosphotriester method in solution
using 4-ethoxypyridine N-oxide [29] or N-methy-
limidazole [30] as nucleophilic catalysts of coupling
reactions.
Trimer 3’-5’-oligoadenylate 3’-5’-À3 was obtained
by a standard solid-phase phosphoramidite method on
ASM-800 synthesizer (Biosset, Russian Federation).
2’-5’-À3: molecullar formula C30H37N15O16P2, M =
925.65, MALDI-mass-spectrum – m/z = 928.12
[(M+H)+], 792.18 [(M–Ade+H)+]; 2’-5’-À3: C30H37
N15O16P2, M = 925.65, m/z = 926.66 [(M+H)
+]; 2’-5’-
À3-epo: C30H35N15O15P2, M = 907.64, m/z = 913.27
[(M+H)+].
Recombinant interferon -2b and human insulin
were manufactured by Interpharmbiotek and Farmak
companies (Ukraine), respectively.
Aqueous solutions of the samples were used. The
solutions of proteins and oligonucleotides were
incubated at 37 °C for 10 min. The concentration of
investigated compounds in the individual solutions and
mixtures was 10–4 M for all oligoadenylates, 10–5 M for
interferon, and 3.5·10–5 M for insulin.
Mass spectrometry analysis was conducted using
MALDI-TOF spectrometer Voyager DE PRO (Applied
Biosystems, USA). The accuracy of mass
determination was 0.05 %, the measurements were
performed in the m/z range of 700–50,000. The proteins
and oligonucleotides were ionized using the sinapinic
acid (Sigma-Aldrich, USA). The molecular mass was
calculated by subtracting one from the m/z value of a
monovalent ion (proton mass = 1.007 Da). The
instrument was calibrated using the calibration mixture
calmix3 from the manufacturer of the mass
spectrometer. The matrix reagent was prepared by
dissolving sinapinic acid (10 mg/ml) in the mixture of
equal volumes of acetonitrile and 0.1 % aqueous
solution of trifluoroacetic acid (Sigma-Aldrich). 1.5–2
µl of the mixture of solutions of the investigated sample
and reagent (1:1) was used for the application. A Linear
working mode of the time-of-flight detector was used
with the applied voltage of 25 kV, time delay of ion
extraction was 500 ns [31].
The fluctuations in the molecular mass value for the
same substance in different spectra can be explained by
the change in the instrument resolution depending on
the analysis parameters and incomplete reproducibility
of peak geometry.
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The spectra were processed with Data Explorer 4.0
software (Applied Biosystems).
Results and Discussion. The method of
MALDI-TOF mass spectrometry was used to study a
number of short 2’-5’ and 3’-5’-oligoadenylates as well
as the proteins insulin and -interferon. Fig. 1 presents
the structures of oligoadenylates. Mass spectra of the
proteins are shown in Fig. 2.
The first stage was investigation of the interaction
of 2’-5’-À3 and a low-molecular protein – human
insulin. The molecular mass obtained from the mass
spectrum of insulin (Fig. 2, a) is 5,800.8 Da which is
close to the theoretical value (5,807.6 Da, error 0.12 %)
and is in good agreement with the data obtained in other
works [26]. The peaks with m/z 11,613 and 17,411
correspond to monocharged complexes containing two
and three insulin molecules, respectively, (a proton is
bound to the aggregate of two or three molecules),
while the peak at 2,896 belongs to a dicharged (doubly
protonated) insulin molecule. The peak with m/z =
6,014 may correspond to the product of matrix-protein
interaction: m/z of one of the main peaks, corres-
ponding to (M – OH)+ fragment in the mass spectrum of
sinapinic acid, is 207.07. The peaks in this region are
also observed in the spectra of insulin mixtures with
oligonucleotides.
The mass spectrum of insulin mixture with 2’-5’-À3
(Fig. 3, a) contains the peaks with m/z values of 929.1;
2,908.6; 5,801.3; 11,649 and 17,402 which correspond
(within the limit of accuracy of the instrument) only to
free components of the mixture (oligonucleotide and
protein). Therefore, the interaction of insulin and
2’-5’-À3 was not registered in vitro.
The following series of experiments involved
á-interferon, widely used in the therapy of viral
diseases such as hepatitis C. Fig. 2, b presents the mass
spectrum of -interferon, where the peak with m/z =
19,265 corresponds to monocharged ion of the protein.
The theoretical molecular mass of interferon -2b
obtained from the amino acid sequence is 19,271 Da
(DrugBank: http:// www.drugbank.ca/drugs/
DB00105), i.e. the deviation of the experimental value
is 0.04 %. The peaks with m/zvalues 9,618 and 6,417
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Fig. 1. Structures of investigated
oligoadenylates
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Fig. 2. MALDI mass spectra of insulin (a) and -interferon (b)
belong to di- and tricharged ions of á-interferon (m/z
values are two and three times lower than that for
monovalent ion, respectively). The peak with m/z value
of 38,610 corresponds to monoprotonated complex of
two interferon molecules. The mass spectrometry data
obtained for á-interferon by us are in good agreement
with the literature [32, 33].
Fig. 3, b presents the fragment of the spectrum of
the mixture of interferon and 2’-5’-À3 which
demonstrates the formation of protein complexes with
one or several oligonucleotide molecules. Contrary to
the insulin–2’-5’-À3 mixture whose spectrum contains
only peaks belonging to its components, the addition of
2’-5’-À3 to interferon led to considerable changes in the
mass spectrum. In particular, the peaks with m/z values
20,179, 21,112, 22,044, 22,998 and 23,899 appear in
the spectrum of interferon–2’-5’-À3 system. They
correspond to the complexes composed of one
interferon molecule and one to five 2’-5’-À3 molecules.
The obtained molecular mass values are in good
agreement with theoretical ones. Thus, the deviation of
experimental m/z from the theoretically calculated
value for protein complexes with one or two 2’-5’-À3
molecules is 0.09 and 0.06 %, respectively.
As the complexes are detected after the impact of
laser ionization, their registration in mass spectra
suggests rather strong interaction between the
molecules of protein and oligoadenylate. It should be
noted that the formation of protein complex with
several ligand molecules is more difficult as compared
to the complex with a single ligand; it also decomposes
at the ionization step (before registration by the
instrument) more easily. Therefore, the formation of
stable multiple aggregates confirms quite strong
binding of -interferon to the ligand.
At the next stage we studied the interaction of
á-interferon with a natural 3’-5’-triadenylate which
differs from 2’-5’-À3 only by the type of inter-
nucleotide bonds. The mass spectrum of insulin and
3’-5’-À3 mixture (Fig. 4) registers multiple interaction
of a protein molecule with one or several molecules of
oligonucleotide. Similar to 2’-5’-À3, the formation of
stable complexes containing one to five molecules of
triadenylate per protein molecule was detected. The
spectrum of the mixture also contains a group of less
intense peaks corresponding to doubly protonated
complexes (in the range of m/z 9,600–11,300).
3’-Epoxy-modified oligoadenylate 2’-5’-À3-epo
was selected for further experiments. As shown in
previous works of many authors, even a slight
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Fig. 3. MALDI mass spectra of the mixtures of insulin (a) and
-interferon (b) with oligoadenylate 2’-5’-À
3
à
Fig. 4. MALDI mass spectrum of the mixture of -interferon and
oligoadenylate 3’-5’-À
3
modification of the 2-5A structure may result in sharp
changes in its biological activity [1, 3, 5, 6]. The above
mentioned analogue of 2’-5’-triadenylate also
demonstrates interesting and diverse biological activity
[30, 34–36].
The mass spectrum of the mixture of insulin and
2’-5’-À3-epo consists only of the peaks of
oligonucleotide and protein (Fig. 5, a). No additional
peaks were registered, i.e. the mass spectrum of the
mixture is actually the superposition of the spectra of its
components. The peak with m/z = 6,023 may be the
product of sinapinic acid binding to the protein (M =
224.21). Therefore, as in the case of non-modified
trimers, no interaction of 2’-5’-À3 analogue with
insulin was registered in vitro.
The mass spectrum of the á-interferon mixture with
2’-5’-À3-epo (Fig. 5, b) contains a new peak with m/z =
20,177 which suggests the binding of á-interferon to
2’-5’-À3-epo molecule (the deviation from the theo-
retical value of molecular mass of the complex is 0.06
%). There are also two less intense peaks in the spec-
trum corresponding to the complexes of the interferon
molecule and two and three molecules of oligo-
nucleotide. Thus, 2’-5’-À3-åðî also binds to interferon.
It is commonly assumed that antiviral properties of
phosphorylated 2-5A are related to their capability of
activating RNAse L, which, in turn, destroys viral
mRNA [1, 8–11, 37–39]. However, “core” 2-5A and
their analogues are remarkable also for other properties
which cannot be explained by the abovementioned
mechanism. In particular, these properties include the
prevention of tissue rejection after transplantation, the
effect on proliferation and apoptosis of stem cells,
cardioprotecting properties, etc. [30, 34, 35].
Therefore, new approaches should be elaborated
which would allow determining the mechanisms for
unusual biological activities of “core” oligoadenylates.
One of possible explanations may be the ability of
oligoadenylates to interact with some proteins that
determines their biological activity.
In our previous research the method of fluorescent
spectroscopy was used to demonstrate the interaction of
2’-5’-oligoadenylates and a number of their analogues
with albumin and interferon, with no binding to
immunoglobulin G [36]. The results of numerous
studies on the mechanisms of antiviral activity of 2-5A
suggest its direct relation to the activity of interferon [1,
3, 8–10, 38, 39]. The analysis of oligoadenylate-inter
feron systems performed using the mass spectrometry
method allowed us to discover rather stable interactions
between this protein and oligonucleotides. It should be
noted that the mass spectra of mixtures incubated for 24
hours at 4 °C were identical to those obtained after 10
min of incubation at 37 °C.
Conclusions. Our work presents the first study on
the interaction of oligonucleotides and proteins in vitro
by MALDI-TOF method.
It was shown that under the applied experimental
conditions the natural 2’-5’-À3, its epoxy analogue
2’-5’-À3-epo and 3’-5’-triadenylate are not capable of
binding to insulin. At the same time, all the investigated
2’-5’ and 3’-5’-oligoadenylates can bind to
á-interferon, which is involved in 2’-5’-OAS/RNAse L
system, in the ratio of one to five molecules of the
ligand per protein molecule, to form stable complexes.
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Fig. 5. MALDI mass spectra of the mixtures of insulin (a) and
-interferon (b) with oligoadenylate 2’-5’-À
3
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Äîñë³äæåííÿ âçàºìîä³¿ îë³ãîàäåí³ëàò³â ç á³ëêàìè
in vitro ìåòîäîì ìàñ-ñïåêòðîìåòð³¿ MALDI-TOF
1
²íñòèòóò ìîëåêóëÿðíî¿ á³îëîã³¿ ³ ãåíåòèêè ÍÀÍ Óêðà¿íè
Âóë. Àêàäåì³êà Çàáîëîòíîãî, 150, Êè¿â, Óêðà¿íà, 03680
2
²íñòèòóò á³îõ³ì³¿ ³ì. Î. Â. Ïàëëàä³íà ÍÀÍ Óêðà¿íè
Âóë. Ëåîíòîâè÷à, 9, Êè¿â, Óêðà¿íà, 01601
Ðåçþìå
Ìåòà. Äîñë³äèòè çäàòí³ñòü «êîðîâèõ» 2'-5'- ³ 3'-5'-îë³ãîà-
äåí³ëàò³â âçàºìîä³ÿòè ç -³íòåðôåðîíîì – êëþ÷îâèì á³ëêîì ñèñ-
òåìè 2'-5'-ÎÀÑ/ÐÍÊàçà L, â³äïîâ³äàëüíî¿ çà ïðîòèâ³ðóñíèé
çàõèñò êë³òèíè. Ìåòîäè. Äëÿ âèâ÷åííÿ âçàºìîä³é á³ëîê–îë³ãîíóê-
ëåîòèä âèêîðèñòàíî ìåòîä ìàñ-ñïåêòðîìåòð³¿ MALDI-TOF. Ðå-
çóëüòàòè. Âñòàíîâëåíî çäàòí³ñòü 2'-5'-À3 òà éîãî åïîêñè-
ìîäèô³êîâàíîãî àíàëîãà 2'-5'-À3-epo çâ’ÿçóâàòèñÿ ç -³íòåðôåðî-
íîì in vitro. Ç öèì á³ëêîì ìîæå òàêîæ âçàºìîä³ÿòè ³ 3'-5'-òðèà-
äåí³ëàò. Ïðè öüîìó äî ìîëåêóëè -³íòåðôåðîíó îäíî÷àñíî ìîæå
ïðèºäíóâàòèñÿ â³ä îäí³º¿ äî ï’ÿòè ìîëåêóë ë³ãàíäó. Ó òîé æå ÷àñ
ç ³íñóë³íîì óñ³ äîñë³äæåí³ îë³ãîíóêëåîòèäè íå çâ’ÿçóþòüñÿ. Âèñ-
íîâêè. Ïîêàçàíî, ùî «êîðîâ³» 2'-5'- ³ 3'-5'-òðèàäåí³ëàòè ìíîæèí-
íî âçàºìîä³þòü ç -³íòåðôåðîíîì ç óòâîðåííÿì ñò³éêèõ êîìï-
ëåêñ³â. Îäíàê âîíè íå çâ’ÿçóþòüñÿ ç ³íñóë³íîì, ÿêèé íå º êîìïîíåí-
òîì ñèñòåìè 2'-5'-ÎÀÑ/ÐÍÊàçà L.
Êëþ÷îâ³ ñëîâà: îë³ãîàäåí³ëàòè, ³íñóë³í, -³íòåðôåðîí,
ìàñ-ñïåêòðîìåòð³ÿ MALDI-TOF.
Ñ. Ì. Ëåâ÷åíêî, À. Â. Ðåáðèåâ, Â. Â. Òêà÷óê, Ë. Â. Äóáåé,
È. ß. Äóáåé, Ç. Þ. Òêà÷óê
Èññëåäîâàíèå âçàèìîäåéñòâèÿ îëèãîàäåíèëàòîâ ñ áåëêàìè in vitro
ìåòîäîì ìàññ-ñïåêòðîìåòðèè MALDI-TOF
Ðåçþìå
Öåëü. Èññëåäîâàòü ñïîñîáíîñòü «êîðîâûõ» 2'-5'- è 3'-5'-îëèãîà-
äåíèëàòîâ âçàèìîäåéñòâîâàòü ñ -èíòåðôåðîíîì – êëþ÷åâûì
áåëêîì ñèñòåìû 2'-5'-ÎÀÑ/ÐÍÊàçà L, îòâåòñòâåííîé çà ïðîòè-
âîâèðóñíóþ çàùèòó êëåòêè. Ìåòîäû. Äëÿ èçó÷åíèÿ âçàèìîäå-
éñòâèé áåëîê–îëèãîíóêëåîòèä èñïîëüçîâàí ìåòîä
ìàññ-ñïåêòðîìåòðèè MALDI-TOF. Ðåçóëüòàòû. Óñòàíîâëåíà
ñïîñîáíîñòü 2'-5'-À3 è åãî ýïîêñè-ìîäèôèöèðîâàííîãî àíàëîãà
2'-5'-À3-åpo ñâÿçûâàòüñÿ ñ -èíòåðôåðîíîì in vitro. Ñ ýòèì áåë-
êîì ìîæåò òàêæå âçàèìîäåéñòâîâàòü è 3'-5'-òðèàäåíèëàò.
Ïðè ýòîì ê ìîëåêóëå -èíòåðôåðîíà îäíîâðåìåííî ìîæåò ïðè-
ñîåäèíÿòüñÿ îò îäíîé äî ïÿòè ìîëåêóë ëèãàíäà. Â òî æå âðåìÿ ñ
èíñóëèíîì âñå èçó÷åííûå îëèãîíóêëåîòèäû íå ñâÿçûâàþòñÿ. Âû-
âîäû. Ïîêàçàíî, ÷òî «êîðîâûå» 2'-5'- è 3'-5'-òðèàäåíèëàòû ñïî-
ñîáíû ê ìíîæåñòâåííîìó âçàèìîäåéñòâèþ ñ -èíòåðôåðîíîì ñ
îáðàçîâàíèåì óñòîé÷èâûõ êîìïëåêñîâ. Îäíàêî îíè íå ñâÿçûâà-
þòñÿ ñ èíñóëèíîì, íå ÿâëÿþùåìñÿ êîìïîíåíòîì ñèñòåìû
2'-5'-ÎÀÑ/ÐÍÊàçà L.
Êëþ÷åâûå ñëîâà: îëèãîàäåíèëàòû, èíñóëèí, -èíòåðôåðîí,
ìàññ-ñïåêòðîìåòðèÿ MALDI-TOF.
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